Eligibility and efficacy of a CPC- and CHX-based antiviral mouthwash for the eliminaion of SARS-CoV-2 (COVID-19) from the saliva.

Eligibility and efficacy of a CPC- and CHX-based antiviral mouthwash for the eliminaion of SARS-CoV-2 (COVID-19) from the saliva. - COVID CHX-CPC

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00026711

Enrollment

Registered

2021-10-07

Start date

2022-01-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reduction of the risk of infection from dental staff during aerosol-generating procedures None

Interventions

Group 1: Test group: cetylpyridinium chloride 0.05% and chlorhexidine 0.05% mouth rinses for 60 sec Group 2: Control group: sterile water for 60 sec

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: COVID-19 positive Capable of rinsing with a mouth rinse for 60 seconds and delivering 4 ml of saliva at each of the four time points

Exclusion criteria

Exclusion criteria: Ventilation Use of an antiseptic mouth rinse in the 48 hours prior to study entry Hypersensitivities or allergies to components of any of the mouth rinses Low viral load < 25 samples by RT-qPCR Pregnancy / breastfeeding Patients with weakened immune systems Xerostomia Tooth extraction less than 2 weeks ago

Design outcomes

Primary

Measure	Time frame
Nucleocapside (ELISA) fraction and virus load (qPCR) at 15 minutes	—

Secondary

Measure	Time frame
Nucleocapside (ELISA) fraction and virus load (qPCR) at 30 and 60 minutes	—

Countries

Germany

Contacts

Public ContactKathrin Becker

Poliklinik für Kieferorthopädie

kathrin.becker@med.uni-duesseldorf.de+49 211 811 8145

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026